546 — Medtecs International Balance Sheet
0.000.00%
- SG$61.57m
- SG$55.57m
- $54.42m
- 57
- 51
- 56
- 58
Annual balance sheet for Medtecs International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 87.3 | 58.7 | 37.6 | 35 | 27.3 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 49.3 | 47.4 | 32.4 | 20.4 | 10.7 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 206 | 163 | 110 | 95.8 | 98.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 31.4 | 44.9 | 57.6 | 53.6 | 26.4 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 246 | 216 | 182 | 167 | 138 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 46 | 20.6 | 25.1 | 33 | 28.3 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 52.2 | 30.4 | 32.3 | 37.6 | 31.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 193 | 185 | 150 | 129 | 106 |
Total Liabilities & Shareholders' Equity | 246 | 216 | 182 | 167 | 138 |
Total Common Shares Outstanding |